NEWS

WASHINGTON, D.C. (Dec. 29, 2025) – We Work For Health commends the Trump administration for recognizing the substantial role corporate insurers and their integrated subsidiaries play in driving up costs and restricting access to care for American families. The administration's announcement of their intent to bring healthcare insurance executives to the table and examine the full scope of insurance industry practices represents the most necessary and critical step toward meani

In April, a bipartisan committee warned Congress that America’s global biosector leadership was potentially on borrowed time, advising that if not for urgent regulatory corrections, China will overtake the U.S. within three years. That same committee has issued an update. The clock is ticking even faster than feared. “Since the publication of that assessment , the trajectory the Commission identified has continued – and in several respects intensified,” said the National Secu

A historic 2025 is coming to a close for America’s biopharmaceutical sector. From coast to coast, dozens of companies announced or broke ground on next-generation research facilities, expanded their stateside manufacturing capacity, and laid the foundation for accelerating medical breakthroughs. According to We Work For Health’s U.S. Biopharma Investment Watch , the industry committed more than $492 billion  in new domestic investment this year. The unprecedented capital depl

WASHINGTON, D.C. (Dec. 19, 2025) We Work For Health released the following statement today in response to the Centers for Medicare & Medicaid Services announcing the Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) models:   “Applying the most favored nation (MFN) pricing models to Medicare Parts B and D – including sweeping Medicare demonstrations that would mandate price controls across broad categories of Part

By: Debbie Hart, CEO, BioNJ and Dan Leonard, Executive Director, We Work For Health Will the epicenter of global medical innovation be in New Jersey or Shanghai? That is a critical question before U.S. policymakers right now, and the stakes arguably couldn’t be higher. How the country fends off China’s rising biopharma sector affects everything from our health and national security to local, state and national economies. Today, the U.S. leads the world in biopharmaceutical in

Over the past decade, China has executed a sustained, long-range strategy to build a globally competitive biopharmaceutical sector. Through coordinated investment and policy, the country has moved from “me-too” products to cutting-edge therapies, while elevating regulatory and manufacturing standards to global norms. And it’s working.   On Dec. 11, We Work For Health convened a full room of stakeholders for a critical discussion on China’s accelerating biopharmaceutical ambit

We Work for Health's Executive Director Dan Leonard recently sat down with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum (NMQF), to discuss his organization's work to ensure fair access to life-saving research and emerging treatments as well as what needs to be done to preserve America's innovation leadership.   The discussion highlighted the public health and economic imperatives of maintaining U.S. competitiveness in biopharmaceutical research

November 26, 2025   (Washington, DC) We Work For Health Executive Director Dan Leonard issued the following statement in response to the administration’s announcement on the Maximum Fair Prices (MFP) for IPAY 2027 selected drugs:   “We Work For Health has been sounding the alarm about the dangers of government price controls since the passage of the Inflation Reduction Act (IRA). This latest announcement from the Administration is yet another troubling consequence of that pol

Members of the Senate Special Committee on Aging convened last week to hear from witnesses on restoring trust in American-made medicines.   The hearing  highlighted urgent concerns about America’s reliance on foreign nations, particularly China, for critical drug ingredients and finished medications.   Witnesses and lawmakers warned that this dependence is compromising patient safety, national security and supply-chain resilience.   As Senator Scott (R-FL) said in his opening

Chinese biotech stock is reportedly “booming” while outperforming its U.S. counterpart, delivering the latest data point in a worrisome trend for America’s patients, economy, and national security.   According to a recent STAT article , while U.S. biotech stock is up 20% this year, China's is up a whopping 80%. At first glance, this could be dismissed as another short-term spike. Similar ones were observed between 2018 and 2021 when a flurry of Chinese drugmakers launched IPO

North Carolina’s life sciences industry is a hub of innovation that drives economic growth and advances health care.   Its research and biotech sectors employ more than 226,000 people  and contribute more than $80 billion  to the state’s economy. Through thousands of clinical trials involving millions of participants, the state plays a central role in finding discoveries that improve patient care nationwide.   That’s where strong intellectual property (IP) protections come in

The urgency for the U.S. to maintain its leadership in biotechnology – especially in competition with China – is growing. This issue came into sharp focus during recent discussions between lawmakers and industry experts at a Senate HELP Committee hearing .    “I recently spoke to a group of biotech leaders,” Sen. Bill Cassidy (R-LA) said. “They, in varying degrees, view China as a collaborator, a competitor and as a threat. When developers are looking outside our country for

As we wrap up IP Month, WWFH Executive Director Dan Leonard sat down for a conversation with David Kappos of the Council for Innovation Promotion. As former Under Secretary of Commerce and Director of the U.S. Patent and Trademark Office and Vice President and Chief Intellectual Property Lawyer at IBM, Kappos is an expert in the innovation and intellectual property (IP) space.  Throughout the conversation, Kappos underscores the fundamental importance of strong IP protections

We Work For Health Executive Director Dan Leonard recently sent a letter to the Food and Drug Administration (FDA) commending its commitment to expanding domestic drug research and manufacturing capabilities. He also urged the agency to encourage continued progress in fortifying the nation’s pharmaceutical supply chain. For more on how U.S. investments are driving innovation, explore WWFH's Biopharma Investment Watch .

During October’s Intellectual Property Month, WWFH’s Executive Director Dan Leonard sat down with Laura Schoppe of Tech Pipeline  for a timely conversation about the future of American innovation. With China's biopharmaceutical sector gaining ground and policy challenges mounting at home, Laura's insights come at a critical moment. Drawing on her experience in academic technology transfer and biopharmaceutical innovation, Laura offers a nuanced look at both the opportunities

In recognition of Intellectual Property (IP) Month, We Work For Health 's Executive Director Dan Leonard sat down with Stephen Ezell of the Information Technology and Innovation Foundation (ITIF) to explore the state of America’s innovation ecosystem. Their conversation covered pressing topics such as rising competitive challenges from China and how misguided policy choices could impact the U.S.’s global standing for generations. Ezell, who directs ITIF’s Center for Life Sci

Last week, the Senate Judiciary Committee’s Subcommittee on Intellectual Property held a hearing on the Patent Eligibility Restoration Act  (PERA) , which would bring much-needed clarity to the patent system that is essential for the United States maintaining its global leadership in the life sciences.   October is Intellectual Property Month, and We Work For Health is continuing to call on policymakers to prioritize meaningful reforms and modernize the intellectual property

A Hong Kong-based healthcare expert recently warned that China's biotechnology sector has achieved such rapid advancement and cost advantages that it may fundamentally reshape the global pharmaceutical landscape and potentially displace the United States as the world’s innovator of new cures. Cui Cui, managing director and head of Asia healthcare research at Jefferies, recently spoke to Endpoints News about the dramatic transformation of China’s life sciences sector and the

There is yet another metric depicting how China is aggressively readying itself to challenge, and potentially surpass,...

America's biopharmaceutical sector is delivering unprecedented investment in domestic innovation and manufacturing capacity. In 2025...

Former FDA commissioner Scott Gottlieb recently appeared on an Endpoints News video series to share insight  into China's rapid ascent in...

China’s life science footprint once functioned as little more than a factory on the global stage. It supplied high-volume generics and...

The House Energy and Commerce Subcommittee on Health recently held a hearing, Examining Policies to Enhance Seniors’ Access to...

By: Dan Leonard, Executive Director, We Work For Health The decades-long partnership between the federal government, research-focused...

The Most Favored Nation (MFN) drug pricing policy proposal remains an administration focus since a May executive order . Most recently,...

Together with the Council for Innovation Promotion, We Work For Health recently hosted a roundtable discussion focused on the pivotal...

By: Dan Leonard, Executive Director, We Work For Health Kansas is both a driver and a beneficiary of the most sustained period of growth...

Roundtable Highlights How Strong IP Protections Drive Breakthroughs and Benefit Patients RALEIGH, NC (August 12, 2025) — On Tuesday,...

By: Tom Kowalski, Co-Chair, We Work For Health Recent efforts to revive the so-called “Most Favored Nation” (MFN) drug pricing policy...

The Bayh-Dole Act of 1980 enables universities to retain intellectual property rights to discoveries made with federal funding, spurring...

While some in Washington are proposing damaging drug pricing policies, including “Most Favored Nation,” China is gaining ground in...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health What do North Carolina’s incredible universities have in common, in...

A common depiction of a U.S. biopharmaceutical industry worker shows someone working alone in a sterile lab environment. They wear a...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health Smart policymaking and American ingenuity have combined to create an...

American innovation has long been the envy of the world, built on a foundation of strong intellectual property protections,...

By Dan Leonard, Executive Director, We Work For Health Global innovation is a long-distance race. For decades, the United States has led...

WASHINGTON, D.C. (May 12, 2025) — We Work For Health released the following statement in response to the executive order signed Monday...

By: Dan Leonard, Executive Director, We Work For Health The Administration’s latest proposal to revive the Most Favored Nation (MFN) drug...

WASHINGTON, D.C. (May 5, 2025) — We Work For Health released the following statement in response to reports around foreign reference...

By Dan Leonard, Executive Director, WWFH The Inflation Reduction Act (IRA), signed into law in August 2022, contains a healthcare...

This Saturday, we observe World Intellectual Property Day , a moment to reflect on how intellectual property (IP) rights enable...

We Work For Health recently hosted a Congressional briefing about the IRA "pill penalty" and the importance of passing the Ensuring...

By Tom Kowalski, WWFH Co-Chair Chronic disease has contributed to declining life expectancy in the United States , a disturbing pattern...

We Work For Health released the following statement on the Trump Administration’s April 15 executive order regarding the Inflation...

Small-molecule drug investment has fallen 68%—and 74% for diseases mainly affecting Medicare patients—since the IRA was introduced FOR...

The lead sponsors of the Ensuring Pathways to Innovative Cures (EPIC) Act addressed a room full of Congressional office employees and...